



KENNY C. GUINN  
Governor

STATE OF NEVADA  
DEPARTMENT OF HUMAN RESOURCES  
**DIVISION OF HEALTH CARE FINANCING AND POLICY**  
NEVADA MEDICAID

MICHAEL J. WILLDEN  
Director

CHARLES DUARTE  
Administrator

**NOTICE OF OPEN PUBLIC MEETING**

The Division of Health Care Financing and Policy ("DHCFP"), Pharmacy and Therapeutics Committee will conduct a public meeting on **October 28th, 2004** beginning at **1:00 p.m.** at the following location:

**CARSON CITY**  
**Legislative Building**  
**401 South Carson Street**  
**Room 3137**  
**Carson City**

**LAS VEGAS**  
**Grant Sawyer Building**  
**555 E. Washington Avenue**  
**Room 4401**  
**Las Vegas**

Reasonable efforts will be made to assist and accommodate physically challenged persons desiring to attend the meeting. Please call Nancy Davis at: 775-684-3715 or toll free at: 1-800-992-0900, ext. 43715 in advance, but no later than two working days prior to the meeting, so that arrangements may be conveniently made.

**Below is an agenda of all items scheduled to be considered. Unless otherwise noted, items may be taken out of order at the discretion of the Chairperson.**

**Public comment may be limited to 5 minutes per person at the discretion of the Chairperson.**

**AGENDA**

- I. Call to Order and Roll Call
- II. \*Review and Approval of July 14<sup>th</sup> and August 12<sup>th</sup> Meeting Minutes
- III. Report on Preferred Drug List Implementation - First Health Services
- IV. \*Approval of Drug Classes to be Reviewed
  - A. October 2004
    - 1. Leukotriene Modifiers
    - 2. Antiemetics (oral)
    - 3. Inhaled Anticholinergics
    - 4. Erectile Dysfunction Agents
  - B. January 2005
    - 1. Serotonin Receptor Agonists ( Triptans)
    - 2. Suggestions or requests from Committee
- V. Leukotriene Modifiers
  - A. Public Comment
  - B. Drug Class Review – First Health Services – A general overview and comparison of the available drugs within this class will be presented
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Each Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \*Committee Discussion and Approval of Drugs for Inclusion in the PDL

1100 E. William Street, Suite 102, Carson City, Nevada 89701  
(775) 684-3600

- VI. Antiemetics (Oral)
  - A. Public Comment
  - B. Drug Class Review – First Health Services – A general overview and comparison of the available drugs within this class will be presented
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Each Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \*Committee Discussion and Approval of Drugs for Inclusion in the PDL
  
- VII. Inhaled Anticholinergics
  - A. Public Comment
  - B. Drug Class Review – First Health Services – A general overview and comparison of the available drugs within this class will be presented
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Each Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \*Committee Discussion and Approval of Drugs for Inclusion in the PDL
  
- VIII. Erectile Dysfunction Agents
  - A. Public Comment
  - B. Drug Class Review – First Health Services – A general overview and comparison of the available drugs within this class will be presented
  - C. \*Committee Discussion and Action
    - 1. Approve Clinical/Therapeutic Equivalency of Agents in Each Class
    - 2. Identify Exclusions/Exceptions for Certain Patient Groups
  - D. Presentation of Recommendations for Preferred Drug List (PDL) Inclusion by First Health Services and the Division of Health Care Financing and Policy
  - E. \*Committee Discussion and Approval of Drugs for Inclusion in the PDL
  
- IX. Old Business
  - A. Discussion regarding Provigil’s inclusion on the Preferred Drug List
  - B. \*Committee discussion and action on Provigil’s inclusion on the Preferred Drug List
  
- X. Review of January 27, 2005, Meeting Location, Date, and Time
  
- XI. Public Comment
  
- XII. \*Adjournment

**\* Denotes items, including subparts, on which an action may be taken.**

This notice and agenda has been posted on or before 9:00 a.m. on the third working day before the meeting at the following locations:

**Notice of this meeting will be available on or after the posting date of this Agenda at the DHCFP Web site ([dhcftp@state.nv.us](mailto:dhcftp@state.nv.us)).**

**Posting of the Agenda will be at the Nevada Medicaid Central offices in Carson City and Las Vegas; Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County**

**Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a copy of the action items will be mailed to you. They may also be reviewed Monday through Friday from 9:00 a.m. until 5:00 p.m., or at the meeting. Please call at least one day ahead for an appointment for document review. Written comments on the proposed changes may be sent to the DHCFP, 1000 E. William Street, Suite 102, Carson City, NV 89701.**

**All persons that have requested in writing to receive the Open Meeting Agenda have been duly notified by mail or e-mail.**

**Anyone presenting documents for consideration during the public comment portion of the meeting must provide sufficient copies for each member of the committee and the official record. Copies are to be distributed at the time of the meeting and should be provided at both meeting locations; DHCFP or its contractor will not distribute public comment information or materials prior to the public meeting.**